Intervention not reported
Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin receptor blocker (medium‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin‐converting enzyme inhibitor · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus medium‐ dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Beta‐blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Intervention not reported
High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High vs low dose Systolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High vs low dose Diastolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Calcium channel blocker (any dose) Mean duration of 3 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Beta‐blocker/thiazide combination (any dose) Mean duration of 10 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Intervention not reported
Angiotensin receptor blocker (high‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Total mortality · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors showed no clear difference in total mortality compared with all angiotensin receptor blockers (ARBs) (moderate certainty).
1 finding from 1 review
Cardiovascular events · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors showed no clear difference in total cardiovascular events compared with all angiotensin receptor blockers (ARBs) (low certainty).
1 finding from 1 review